Securities Code: 002907
Securities Abbreviation: Huasen Pharmaceutical
Announcement No.: 2026-054
Chongqing Huasen Pharmaceutical Co., Ltd.
Announcement on Company's Partial Products Being Selected in the 12th National Centralized Drug Procurement
The Company and the Board of Directors guarantee the information disclosed is true, accurate, and complete, and contains no false representations, misleading statements, or material omissions.
On July 31, 2026, Chongqing Huasen Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") participated in the 12th National Centralized Drug Procurement organized by the National Joint Procurement Office for Drug Procurement (hereinafter referred to as the "Joint Procurement Office"). According to the "Public Announcement of Preliminary Selection Results for the 12th Batch of National Centralized Drug Procurement" issued by the Joint Procurement Office, the Company's product, Edrophonium Chloride Injection, has been preliminarily selected for this centralized procurement. The relevant situation is hereby announced as follows:
I. Basic Information of Preliminary Selected Drug